AZD0516 Study for Metastatic Prostate Cancer Initiated
A study has been initiated to evaluate the safety and tolerability of AZD0516 in metastatic prostate cancer patients.
Asset / Drug
Drug and asset intelligence for AZD0516 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.